<DOC>
	<DOCNO>NCT01660750</DOCNO>
	<brief_summary>This dose finding pilot study evaluate safety determine maximum tolerate dose combination carfilzomib cyclophosphamide dexamethasone ( Car-Cy-Dex ) prior autologous stem cell transplant ( ASCT ) patient newly diagnose transplant eligible multiple myeloma .</brief_summary>
	<brief_title>A Safety Study Carfilzomib , Cyclophosphamide &amp; Dexamethasone Prior ASCT Patients With Newly Diagnosed Myeloma</brief_title>
	<detailed_description>This dose finding pilot study evaluate safety determine maximum tolerate dose combination carfilzomib cyclophosphamide dexamethasone ( Car-Cy-Dex ) prior autologous stem cell transplant ( ASCT ) patient newly diagnose transplant eligible multiple myeloma . The study also explore efficacy Car-Cy-Dex include overall response induction therapy , overall response 3 6 month post ASCT , time progression , progression free survival , time next therapy occur within 6 month post ASCT .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Cytopathologically histologically confirm diagnosis MM Measurable disease , indicate one following : Serum Mprotein ≥ 1.0 g/dL Urine Bence Jones protein ≥ 200 mg/24 hr Elevated Free Light Chain per International Myeloma Working Group ( IMWG ) criteria Males female ≥ 18 year age Life expectancy 5 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Adequate hepatic function , bilirubin &lt; 2 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3.5 time ULN Serum Creatinine Clearance ( CrCl ) ≥ 30 mL/min , either measure calculate use standard formula ( e.g . Cockcroft Gault ) Additional Laboratory Requirements Absolute neutrophil count ( ANC ) ≥1.0 x 109/L Hemoglobin ≥8 g/dL [ transfusion permit ] Platelet count ≥50.0 x 109/L Screening ANC independent granulocyteand granulocyte/macrophage colony stimulate factor ( GCSF GMCSF ) support least 1 week pegylated GCSF least 2 week Patients may receive RBC platelet transfusion , clinically indicate , accordance institutional guideline Written inform consent accordance federal , local , institutional guideline Patients must agree practice contraception Male patient must agree donate semen sperm . Patients nonsecretory hyposecretory MM Prior treatment MM ( prior radiation therapy dexamethasone 160 mg spinal cord compression allow . Other limited field radiation involve ≤ 1/3 pelvic area also allow ) Plasma cell leukemia Pregnant lactating female Major surgery within 21 day prior first dose Congestive heart failure ( CHF ) ( New York Heart Association class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention myocardial infarction previous six month Acute active infection require systemic antibiotic , antiviral , antifungal within 14 day prior first dose Patients receive active treatment intervention malignancy patient , Investigator 's discretion , may require active treatment intervention malignancy within 8 month start study treatment . Serious psychiatric medical condition could interfere treatment Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose and/or within 14 day study treatment Contraindication require concomitant drug , include antiviral ( e.g . Valacyclovir ) protonpump inhibitor ( e.g . lansoprazole ) . Corticosteroid therapy dose equivalent dexamethasone ≥ 1.5 mg/day prednisone ≥ 10 mg/day . ( Steroid use allow necessary treat spinal cord compression and/or hypocalcaemia . ) Patients require program oral IV fluid hydration contraindicate , e.g . due preexist pulmonary , cardiac , renal impairment Patients primary systemic amyloidosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>newly diagnose multiple myeloma</keyword>
	<keyword>transplant eligible multiple myeloma</keyword>
</DOC>